{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["17(1)"],"submitter":["Maltais F"],"funding":["Boehringer Ingelheim"],"pubmed_abstract":["Background
Two replicate, double-blind, placebo-controlled, 6-week crossover studies assessed the effect of the once-daily long-acting β2-agonist olodaterol 5 μg and 10 μg on constant work-rate cycle endurance in patients with moderate to very severe chronic obstructive pulmonary disease.Methods
Patients received placebo, olodaterol 5 μg once daily (QD) and olodaterol 10 μg QD in a randomised order for 6 weeks each, with a 2-week washout period in between. The primary end point was change in endurance time during constant work-rate cycle ergometry to symptom limitation at 75 % maximal work capacity after 6 weeks of treatment (2 h post-dose), based on log10-transformed data. Key secondary end points were inspiratory capacity at isotime and intensity of breathing discomfort a"],"journal":["Respiratory research"],"pagination":["77"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4936013"],"repository":["biostudies-literature"],"pubmed_title":["Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week crossover studies."],"pmcid":["PMC4936013"],"pubmed_authors":["De Sousa D","Kirsten AM","Decramer M","Maltais F","Hamilton A","Voß F"],"additional_accession":[]},"is_claimable":false,"name":"Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week crossover studies.","description":"Background
Two replicate, double-blind, placebo-controlled, 6-week crossover studies assessed the effect of the once-daily long-acting β2-agonist olodaterol 5 μg and 10 μg on constant work-rate cycle endurance in patients with moderate to very severe chronic obstructive pulmonary disease.Methods
Patients received placebo, olodaterol 5 μg once daily (QD) and olodaterol 10 μg QD in a randomised order for 6 weeks each, with a 2-week washout period in between. The primary end point was change in endurance time during constant work-rate cycle ergometry to symptom limitation at 75 % maximal work capacity after 6 weeks of treatment (2 h post-dose), based on log10-transformed data. Key secondary end points were inspiratory capacity at isotime and intensity of breathing discomfort a","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Jul","modification":"2026-06-16T05:48:31.026Z","creation":"2019-03-27T02:17:45Z"},"accession":"S-EPMC4936013","cross_references":{"pubmed":["27383762"],"doi":["10.1186/s12931-016-0389-5"]}}